Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03713515 · ClinicalTrials.gov registry record · Phase 4
Bridging the Evidence-to-practice Gap
A Phase 4 study of Hypertension, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 700
- Enrollment target
- 1
- Study location
NCT03713515: Recruiting Phase 4 study of Hypertension, sponsored by NYU Langone Health.
NCT03713515 is a Phase 4 study of Hypertension that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 700 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03713515, a Phase 4 study of Hypertension, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 700 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed project will address this evidence-to-practice gap by evaluating the effect of practice facilitation (PF) of the intervention implementation fidelity (primary outcome) and clinical measures at 12 months (secondary outcomes).
Primary Outcome
Defined as the percentage of eligible participants who were screened.
Conditions Studied
Interventions
- BEHAVIORAL ALTA
Study Locations (1)
New York
- NYUMC Langone - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2027-11-30 |
| Phase | Phase 4 |
What NCT03713515 shows while recruiting
NCT03713515 is an interventional study that assigns participants to a tested intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which ALTA is the first listed.
NCT03713515 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03713515 about?
NCT03713515 is a clinical study titled "Bridging the Evidence-to-practice Gap". The proposed project will address this evidence-to-practice gap by evaluating the effect of practice facilitation (PF) of the intervention implementation fidelity (primary outcome) and clinical measures at 12 months (secondary outcomes).
What is the current status of trial NCT03713515?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 700 participants. The study started on 2020-12-01. Estimated completion is 2027-11-30.
What conditions does trial NCT03713515 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT03713515?
The interventions under investigation include: ALTA (BEHAVIORAL).
Who is sponsoring clinical trial NCT03713515?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03713515 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03713515's enrollment target sits among peer trials
700 93rd of 470 higher than 378 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
-
MR Antagonist and LSD1
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI